Is heterozygous alpha-1-antitrypsin deficiency type PiZ a risk factor for primary liver carcinoma?

Cancer

Volumn 88, Issue 12, 2000, Pages 2668-2676

  Zhou, Hui ^a   Ortiz Pallardó, M Elena ^b   Ko, Yon ^b   Fischer, Hans Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Alpha 1 antitrypsin deficiency; DNA sequencing; Immunohistochemistry; Isoelectric focusing; Liver carcinoma; Single strand conformational polymorphism

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ISOELECTRIC FOCUSING; LIVER CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0034659888     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2668::AID-CNCR4>3.0.CO;2-G     Document Type: Article

References (50)

1. Billingsley GD, Walter MA, Hammond GL, Cox DW. Physical mapping of four serpin genes: alpha-1-antitrypsin, alpha-1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome 14q32.1. Am J Hum Genet 1993;52:343-53.
2. Norman MR, Mowat AP, Hutchinson DCS. Molecular basis, clinical consequences and diagnosis of alpha-1-antitrypsin deficiency. Ann Clin Biochem 1997;34:230-46.
3. World Health Organization meeting, α1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997;75:397-415.
4. Qu D, Teckman JH, Perlmutter DH. Metabolic liver diseases. Review: α1-antitrypsin deficiency associated liver disease. J Gastroenterol Hepatol 1997;12:404-16.
5. Laurell CB, Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest 1963;15:132-40.
6. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969;73: 934-9.
7. Eriksson S, Hägerstrand I. Cirrhosis and malignant hepatoma in α1-antitrypsin deficiency. Acta Med Scand 1974;195: 451-8.
8. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha-antitrypsin deficiency. N Engl J Med 1986;314:736-9.
9. Abdul-Nasser E, Eriksson S. Risk of hepatobiliary disease in adults with severe α1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996;8:989-94.
10. Hodges JR, Millward-Sadler GH, Barbatis C, Wright R. Heterozygous MZ alpha1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med 1981;304:557-60.
11. Govindarajan S, Ashcavai M, Peters RL. α-1-antitrypsin phenotypes in hepatocellular carcinoma. Hepatology 1981;1: 628-31.
12. Carlson J, Eriksson S. Chronic "cryptogenic" liver disease and malignant hepatoma in intermediate alpha1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol 1985;20:835-42.
13. Rabinovitz M, Gavaler JS, Kelly RH, Prieto M, Van Thiel DH. Lack of increase in heterozygous α1-antitrypsin deficiency phenotypes among patients with hepatocellular and bile duct carcinoma. Hepatology 1992;15:407-10.
14. Propst Th, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W. Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J Hepatol 1994;21:1006-11.
15. Eigenbrodt ML, McCashland TM, Dy RM, Clark J, Galati J. Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease. Am J Gastroenterol 1997;92: 602-7.
16. Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous α1-antitrypsin deficiency. Hepatology 1998;28:1058-63.
17. Perlmutter DH. Alpha-1-antitrypsin deficiency. Semin Liver Dis 1998;18:217-25.
18. Zhou H, Fischer H-P. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998;22:742-8.
19. Wallmark A, Alm R, Eriksson S. Monoclonal antibody specific for the mutant Pi Z alpha-1-antitrypsin and its application in an ELISA procedure for identification of Pi Z gene carriers. Proc Natl Acad Sci U S A 1984;81:5690-3.
20. Anthony PP. Tumours and tumour-like lesions of the liver and biliary tract. In: MacSween RNM, Anthony PP, Scheuer PP, Burt AD, Portmann BC, editors. Pathology of the liver. Edinburgh, London: Churchill Livingstone, 1994; 635-711.
21. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. Cancer 1985;55:124-35.
22. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
23. Sobin LH, Wittekind Ch, editors. UICC TNM classification of malignant tumours. 5th edition. International Union Against Cancer. Philadelphia: J. B. Lippincott, 1997.
24. Weirich G, Hornauer MA, Bruning T, Hofler H, Brauch H. Fixed archival tissue. Purify DNA and primers for good PCR yield! Mol Biotechnol 1997;8:299-301.
25. Bassam BJ, Caetano-Anolles G, Gresshoff PM. Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem 1991;196:80-3.
26. Hummel K. Tabellierte biostatistische Kenngrößen zur blutgruppenserologischen Vaterschaftsbegutachtung. Freiburg i.Br.: Verlag Johannes Krause, 1992:194.
27. Sveger T. Liver disease in α1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294: 1316-21.
28. Sveger T, Eriksson E. The liver in adolescents with α1-antitrypsin deficiency. Hepatology 1995;22:514-7.
29. malton. J Biol Chem 1989;264:13938-45.
30. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. A lag in intracellular degradation of mutant α1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ α1-antitrypsin deficiency. Proc Natl Acad Sci U S A 1994;91:9014-8.
31. Qizilbash A, Young-Pong O. Alpha1-antitrypsin liver disease differential diagnosis of PAS-positive, diastase-resistent globules in liver cells. Am J Clin Pathol 1983;79:697-702.
32. Callea F, Fevery J, DeGroote J, Desmet VJ. Detection of PiZ phenotype individuals by alpha-1-antitrypsin (AAT) immunohistochemistry in paraffin-embedded liver tissue specimens. J Hepatol 1986;2:389-401.
33. Blenkinsopp WK, Haffenden GP. Alpha-1-antitrypsin bodies in the liver. J Clin Pathol 1977;30:132-7.
34. Carlson J, Eriksson S, Hagerstrand I. Intra- and extracellular alpha-1-antitrypsin in liver disease with special reference to Pi phenotype. J Clin Pathol 1981;34:1020-5.
35. Nakopoulou L, Theodoropoulos G, Kotsis L, Papacharalampous N. Demonstration of alpha1-antitrypsin in paraffin sections of hepatoma and cirrhosis. Virchous Arch A 1982;397:163-70.
36. lezzoni J, Gaffey MJ, Stacy EK, Normansell DE. Hepatocytic globules in end-stage hepatic disease: relationship to alpha1-antitrypsin phenotype. Am J Clin Pathol 1997;107: 692-7.
37. Callea F, Brisigotti M, Faa G, Lucini L, Eriksson S. Identification of PiZ gene products in liver tissue by a monoclonal antibody specific for the Z mutant of α1-anti-trypsin. J Hepatol 1991;12:372-6.
38. Perlmutter DH. The cellular basis for liver injury in α1-antitrypsin deficiency. Hepatology 1991;13:172-85.
39. Geller SA, Nichols WS, Dycaico MJ, Felts K, Sorge JA. Hepatocarcinogenesis is the sequel to hepatitis in Z#2 α1-antitrypsin transgenic mice: histopathological and DNA ploidy studies. Hepatology 1994;19:389-97.
40. Nichols WS, Geller SA, Edmond VJ, Dycaico MJ, Sorge JA, Short JM. Hepatocarcinogenesis (Z#2)/mutagenesis during initiation stage. Mutat Res 1998;398:143-9.
41. Carlson JA, Rogers BB, Sifers RN, Finegold MJ, Clift SM, DeMayo FJ, et al. Accumulation of PiZ α1-antitrypsin causes liver damage in transgenic mice. J Clin Invest 1989;83:1183-90.
42. Sharp HL. Alpha-1-antitrypsin: an ignored protein in understanding liver disease. Semin Liver Dis 1982;2:314-28.
43. Eriksson S. α1-antitrypsin deficiency and liver cirrhosis in adults: an analysis of 35 Swedish autopsied cases. Acta Med Scand 1987;221:461-7.
44. Reintoft I, Hägerstrand IE. Does the Z gene variant of alpha-1-antitrypsin predispose to hepatic carcinoma? Hum Pathol 1979;10:419-24.
45. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe α1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996;8:989-94.
46. Elzouki AN, Verbaan H, Lindgren S, Widell A, Carlson J, Eriksson S. Serine protease inhibitors in patients with chronic viral hepatitis. J Hepatol 1997;27:42-8.
47. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989;134:1347-63.
48. Golding M, Sarraf C, Lalani E, Alison MR. Reactive biliary epithelium: the product of a pluripotential stem cell compartment? Hum Pathol 1996;27:872-84.
49. Steinberg P, Steinbrecher R, Radaeva S. Oval cell lines OC/ CDE6 and OC/CDE22 give rise to cholangio-cellular and undifferentiated carcinomas after transformation. Lab Invest 1994;71:700-9.
50. Wu PC, Fang JWS, Lau VKT, Lai CL, Lo CK, Lau JYN. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers: clinical and biological implications. Am J Pathol 1996;149:1167-75.